Zemprocitinib

Zemprocitinib is an investigational new drug that is be evaluated by Lynk Pharmaceuticals for the treatment of ankylosing spondylitis and rheumatoid arthritis.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Zemprocitinib is an investigational new drug that is be evaluated by Lynk Pharmaceuticals for the treatment of ankylosing spondylitis and rheumatoid arthritis. It is an janus kinase 1 (JAK1) inhibitor.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1365631136 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

1 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.